Skip to content
Disclosery

RP Management, LLC

Follow

13F filer, CIK 1507673, New York, NY

RP Management, LLC reported $178,815,027 across 4 holdings for the quarter ended 2024-06-30, in a 13F-HR filed 2024-08-13.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001507673-24-000013

Period
2024-06-30
Reported value
$179M
Holdings
4
Top 10 weight
100%
New
1
Sold out
0

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CYTKnew+980,392$53.1M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

None.

Holdings, Q2 2024

Share positions as resolved from 13F-HR 0001507673-24-000013, largest first. % of portfolio is the value over $178,815,027, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BHVNBIOHAVEN LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: 2,936,507 shares; 2023Q4: 2,936,507 shares; 2024Q1: 2,936,507 shares; 2024Q2: 2,936,507 shares 2,936,507$102M57%0Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 980,392 shares 980,392$53.1M29.71%newTimeline
BCRXBIOCRYST PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: 3,846,154 shares; 2023Q4: 3,846,154 shares; 2024Q1: 3,846,154 shares; 2024Q2: 3,846,154 shares 3,846,154$23.8M13.29%0Timeline
VIRACTA THERAPEUTICS INCVIRACTA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: 3,700 shares; 2023Q4: 3,700 shares; 2024Q1: 3,700 shares; 2024Q2: 3,700 shares 3,700$2K<0.01%0

How Q2 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001507673-24-000013 base2024-08-13acceptance time not in the bulk data set